inforMED
InjuryGAM

NOVOSYN

Received Jul 31, 2026

Report 3003639970-2026-00681 · MDR key 50096519

Device

Generic name

Synthetic Absorbable Braided Suture

Product problems

  • Insufficient Device Problem Information

Patient

Unknown

  • Wound Dehiscence

Narrative

Description of Event or Problem

It was reported an issue with Novosyn suture.The origin of these cases derives from a Survey: B. Braun Novosyn sutures- Post Marketing Clinical Follow Up.The reported cases correspond to adverse events or complications encountered and suture not performing as expected, when using B. Braun Novosyn sutures encountered within the 30 days preceding the survey (that took place between (b)(6)2022 and (b)(6) 2023).Tissue types where B. Braun Novosyn® sutures were used are fascia, ligation, multiple layers, mucosa, superficial skin, intra-dermal, peritoneum, gastrointestinal anastomosis, cornea or sclera, meshfixation, conjunctiva and episiotomy.The specific product code and batch number involved in each individual case is not known.Adverse event description: Gynecologic Surgeon. Suture dehiscence.

Additional Manufacturer Narrative

Summary of investigation:Without code and batch number, we cannot check the information regarding product stock or batch manufacturing records.Without closed samples and/or defective samples a proper analysis cannot be performed.Batch Manufacturing Record:Not possible to check.Conclusion Root Cause Analysis:Root cause: Not applicable, wound dehiscence is an expected undesirable side-effect documented in the Instructions for use of the product.Final conclusion:Without samples we are not in position of studying if the affected product does not fulfil the specifications. In consequence, a proper analysis cannot be done and the case is not confirmed due to lack of evidence. Nevertheless, wound dehiscence is an expected undesirable side effect documented in the instructions for use of the product:Side effectsThe following side effects may be associated with the use ofthis product: pain, granuloma, seroma, hematoma, rejection,enhanced bacterial infectivity, wound dehiscence, anastomoticleak and haemorrhage.Corrective measures:Actions on distributed product of this reference/batch: Based on the conclusion derived from investigation, it is not required to make actions in distributed product.Corrective/Preventive actions: According to our internal procedures, there is no need to establish corrective or preventive actions. Nevertheless, this complaint is recorded for trending analysis to assess if actions are needed in the future.